ClinicalTrials.gg
Active, not recruitingNCT06163326Tranquillo LTEUpdated Sep 28, 2026

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

A Phase 3 interventional study of Ritlecitinib and Ritlecitinib 100 mg in Vitiligo, sponsored by Pfizer. Active, not recruiting at 73 sites in 13 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
394
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Vitiligo with a site in United States — 14 open to participants now, 24 under way, 7 of them phase 3. Vitiligo · United States.

Enrollment
7th of 68
394 · median 37
Started
2024
with 4 others
Phase 3
12 of 80
1 open now
Primary completion
2027-03
later than 9 of 23 live
Registered
67th of 80
by date
Lead sponsor
4 of 80
Pfizer

Among the 80 studies in Vitiligo with a site in United States, this one is the 7th largest by enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2024, is one of 12 in phase 3, reaches primary completion later than 9 of the 23 other live ones, and was the 67th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

14 of the 80 studies in Vitiligo with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Vitiligo with a site in United States, or all of them as a file.
02

Study summary

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).

Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin.

Non-segmental vitiligo is an autoimmune disorder and is the focus of this study. The study will show:

  • if the repigmentation (the recovery of pigmentation) achieved in study B7981040 (also called the "parent study") will stay the same or will further increase if you keep receiving the same study medicine (ritlecitinib 50 milligrams or placebo)
  • Or if more repigmentation can be achieved if you start receiving ritlecitinib 100 milligrams in this study
  • Or how long the repigmentation achieved during the parent study lasts if you start receiving placebo in this study.

This study is seeking for participants who:

  • have non-segmental vitiligo (either active or stable) and
  • received ritlecitinib or placebo for 52 weeks in the parent study. A placebo looks exactly like the study capsule but does not contain any medicine in it.

All participants in this study will receive the study medicine or placebo. The study medicine (ritlecitinib 50 milligrams or 100 milligrams) or placebo are capsules that are taken by mouth at home every day. On study visit days, you must take the medication at the study site, and not at home.

Participants may receive the study medicine or placebo for up to 52 weeks.

The study will look at the experiences of people receiving the study medicine. This will help see if ritlecitinib is better for treating vitiligo.

Participants will be involved in this study for a maximum of 60 weeks. During this time, they will have 9 study visits during the study.

Ritlecitinib 50 mg is an approved drug for the treatment of severe Alopecia Areata (a disease with similar abnormal changes in the body functions like vitiligo) in the US, EU and Japan. China, Great Britain and other market applications are pending.

03

Conditions studied

  • Vitiligo

Browse trials for

Keywords

  • Stable vitiligo
  • Active vitiligo
  • Adults
  • Adolescents
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants ≥18 years of age at Screening in Study B7981040. Adolescents (12 to \<18 years of age at Screening in the parent study) are also eligible for this study if approved by the local IRB/EC and regulatory health authority.
  • Participants who met the eligibility criteria and completed 52 weeks of study intervention for stable or active nonsegmental vitiligo in Study B7981040
  • The BL visit/first dose in Study B7981041 must be within 30 days after the week 52 visit in Study B7981040

Exclusion criteria

Exclusion Criteria:

  • Participant met the parent study (Study 7981040) discontinuation criteria or discontinued the parent study for any safety-related event
  • Any active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
394 participants (actual)

Study arms

  • Experimental
    Arm 1

    Participants who previously received 1 ritlecitinib 50 mg capsule QD orally from BL to Week 52 in Study B7981040. Ritlecitinib 50 mg or Ritlecitinib 100 mg or Placebo will be assigned.

    Drug: Ritlecitinib · Drug: Ritlecitinib 100 mg · Drug: Placebo

  • Experimental
    Arm 2

    Participants who previously received 1 placebo 50 mg capsule QD orally from BL to Week 52 in Study B7981040 Ritlecitinib 50 mg or Ritlecitinib 100 mg or Placebo will be assigned

    Drug: Ritlecitinib · Drug: Ritlecitinib 100 mg · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuation

    To evaluate the long-term safety and tolerability of ritlecitinib in adult and adolescent participants with non-segmental vitiligo

    Time frame: Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)

  2. Incidence of clinically significant laboratory abnormalities

    To evaluate the long-term safety and tolerability of ritlecitinib in adult and adolescent participants with non-segmental vitiligo

    Time frame: Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)

Secondary outcomes

  1. Response based on T-VASI75 at weeks 4, 8, 12, 24, 36 and 52

    Proportion of participants achieving at least a 75% improvement in T-VASI from Baseline

    Time frame: Baseline to week 52

  2. Response based on F-VASI75 at weeks 4, 8, 12, 24, 36 and 52

    Proportion of participants achieving at least a 75% improvement in F-VASI from Baseline

    Time frame: Baseline to week 52

  3. Response based on T-VASI50 at weeks 4, 8, 12, 24, 36 and 52

    Proportion of participants achieving at least a 50% improvement in T-VASI from Baseline

    Time frame: Baseline to Week 52

  4. Response based on F-VASI50 at weeks 4, 8, 12, 24, 36 and 52

    Proportion of participants achieving at least a 50% improvement in F-VASI from Baseline

    Time frame: Baseline to week 52

  5. Response based on T-VASI90 at weeks 4, 8, 12, 24, 36 and 52

    Proportion of participants achieving at least a 90% improvement in T-VASI from Baseline

    Time frame: Baseline to week 52

  6. Response based on F-VASI90 at weeks 4, 8, 12, 24, 36 and 52

    Proportion of participants achieving at least a 90% improvement in F-VASI from Baseline

    Time frame: Baseline to week 52

  7. Response based on T-VASI100 at weeks 4, 8, 12, 24, 36 and 52

    Proportion of participants achieving at least a 100% improvement in T-VASI from Baseline

    Time frame: Baseline to week 52

  8. Response based on F-VASI100 at weeks 4, 8, 12, 24, 36 and 52

    Proportion of participants achieving at least a 100% improvement in F-VASI from Baseline

    Time frame: Baseline to week 52

  9. Patient Global Impression of Severity-Face (PGIS-F) at weeks 24, 36, and 52

    To assess the effect of ritlecitinib compared to placebo on the PGIC-F at weeks 24, 36, and 52

    Time frame: Baseline to week 52

  10. Patient Global Impression of Severity-Overall Vitiligo (PGIS-V) at weeks 24, 36, and 52

    To assess the effect of ritlecitinib compared to placebo on the PGIC-V at Week 24, 36, and 52

    Time frame: Baseline to week 52

  11. Patient Global Impression of Change-Face (PGIC-F) at week 24, 36, and 52

    To assess the effect of ritlecitinib compared to placebo on the PGIC-F at Week 24, 36, and 52

    Time frame: Baseline to week 52

  12. Patient Global Impression of Change- Overall vitiligo (PGIC-V) at weeks 24, 36, and 52

    To assess the effect of ritlecitinib compared to placebo on the PGIC-V at weeks 24, 36, and 52

    Time frame: Baseline to week 52

  13. Proportion of participants achieving disease stabilization

    The difference in the proportion of participants with stable disease at all scheduled timepoints

    Time frame: Baseline to week 52

  14. Percentage change from baseline (%CFB) in F-VASI at weeks 4, 8, 12, 24, 36, and 52

    To compare the efficacy of ritlecitinib 100mg QD, 50mg QD, and placebo

    Time frame: Baseline to week 52

  15. Percentage change from baseline (%CFB) in T-VASI at weeks 4, 8, 12, 24, 36, and 52

    To compare the efficacy of ritlecitinib 100mg QD, 50mg QD, and placebo

    Time frame: Baseline to week 52

  16. Time to loss of response (<F-VASI75 and <T-VASI50 at the same visit).

    To compare the efficacy of ritlecitinib 100 mg QD, 50 mg QD, and placebo

    Time frame: Baseline to week 52

07

Study locations

73 sites
08

References and documents

Publications

  • Lukic T, Ghosh P, Napatalung L, Wang C, Kurosky SK, Hamzavi I, Sinclair R, Xiang L, Steil K, Rosmarin D, Parsad D, Ezzedine K, Adiri R. Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo. Dermatol Ther (Heidelb). 2026 Jul;16(7):3709-3727. doi: 10.1007/s13555-026-01724-y. Epub 2026 May 22. PubMed 42171987 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Mar 2027, 38 months after the start.

Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's planned 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2023
First posted
Dec 8, 2023
StartActual
Jan 19, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06163326
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 8, 2023
Start date
Jan 19, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion